Introduction to HOTAIR (G100124700)

Target Name: HOTAIR

NCBI ID: G100124700

HOTAIR

Introduction to HOTAIR
HOTAIR, also known as HOX Transcript Antisense RNA, is a long non-coding RNA (lncRNA) that has gained significant attention in recent years as a potential drug target or biomarker in various diseases. In this article, we will explore the role of HOTAIR and its implications in different pathological conditions.

What is HOTAIR?
HOTAIR is a lncRNA that was originally discovered in 2007 as a transcript originating from the HOXC gene locus. It was found to be overexpressed in breast cancer and is known for its ability to modulate gene expression through interactions with chromatin remodeling complexes. HOTAIR is transcribed from the antisense strand of the HOXC locus and is subsequently processed into a mature RNA molecule.

HOTAIR as a Drug Target:
The ability of HOTAIR to influence gene expression through epigenetic mechanisms makes it an attractive target for therapeutic interventions. Researchers have been exploring various strategies to inhibit HOTAIR expression or disrupt its interactions with chromatin remodeling complexes. Several studies have shown that downregulation of HOTAIR can lead to decreased cell proliferation and increased sensitivity to chemotherapy in cancer cells.

One approach to targeting HOTAIR is through RNA interference (RNAi), where small interfering RNAs (siRNAs) are designed to specifically bind to and degrade the HOTAIR transcript. This approach has shown promising results in preclinical studies, where it led to reduced tumor growth and increased survival rates in animal models.

Another strategy is the development of small molecule inhibitors that can disrupt the interactions of HOTAIR with its binding partners. By interfering with these interactions, it is possible to prevent the association of HOTAIR with the chromatin remodeling complexes, thereby reducing its influence on gene expression. Although this approach is still in its early stages, initial studies have shown encouraging results in inhibiting HOTAIR-mediated gene repression.

HOTAIR as a Biomarker:
Apart from being a potential drug target, HOTAIR has also been investigated as a biomarker in various diseases. Its dysregulation has been observed in several malignancies, including breast, colorectal, and hepatocellular cancers. High levels of HOTAIR expression have been associated with advanced disease stages, poor prognosis, and resistance to therapy.

In breast cancer, for example, studies have shown that HOTAIR expression levels can stratify patients into different risk groups. Patients with high HOTAIR expression have a higher likelihood of disease recurrence and poorer overall survival rates compared to those with low HOTAIR expression. This highlights the prognostic potential of HOTAIR as a biomarker in breast cancer management.

Similarly, in hepatocellular carcinoma (HCC), increased expression of HOTAIR has been correlated with tumor progression, metastasis, and decreased patient survival. HOTAIR levels have also been found to positively correlate with tumor size, vascular invasion, and tumor grade, making it a potential prognostic biomarker in HCC.

Conclusion:
HOTAIR has emerged as a significant molecule in both research and clinical settings. Its ability to influence gene expression through epigenetic mechanisms positions it as a potential drug target for therapeutic interventions. RNA interference and small molecule inhibitors hold promise in targeting HOTAIR and preventing its involvement in various diseases.

Furthermore, HOTAIR's dysregulation in various malignancies makes it an attractive biomarker for diagnostic and prognostic purposes. Its expression levels can provide valuable information about disease progression, treatment response, and overall patient outcome.

Moving forward, further research and clinical validation are required to fully understand the therapeutic potential and clinical utility of HOTAIR as a drug target and biomarker. Continued efforts in this area may pave the way for new treatment strategies and improved patient management in diseases where HOTAIR plays a critical role.

Protein Name: HOX Transcript Antisense RNA

The "HOTAIR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HOTAIR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets